NCT03059251View on ClinicalTrials.gov

Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina

CompletedOBSERVATIONAL
Enrollment

2

Participants

Timeline

Start Date

August 31, 2017

Primary Completion Date

March 30, 2019

Study Completion Date

March 30, 2019

Conditions
Chronic Lymphocytic Leukemia
Interventions
BIOLOGICAL

Obinutuzumab

Obinutuzumab will be administered as intravenous infusion for 6 cycles (28 days per cycle): 100 milligrams (mg) on day 1 Cycle 1, 900 mg on day 2 Cycle 1, 1000 mg on days 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6.

Trial Locations (3)

Unknown

Clínica Peuyrredón, Buenos Aires

Hospital Italiano de Buenos Aires, Buenos Aires

Hospital Municipal Teodoro Alvarez, Buenos Aires

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03059251 - Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina | Biotech Hunter | Biotech Hunter